chronic prostatitis/chronic pelvic pain syndrome
Conditions
Interventions
Standard treatment for prostatitis:Doxazosin (manufacturer not limited), 4mg, qd, swallowed, taken for 4 weeks
For patients with prostate fluid white blood cell count>10/HP, combination therapy with levofloxacin (manufacturer not limited), 0.5g, qd, taken after meals.
Standard treatment for prostatitis+Extracorporeal shortwave therapy device:Add extracorporeal shortwave therapy device to the treatment plan of the control group. The extracorporeal shortwave therapy
Sponsors
Xiangya Hospital,Central South Univerity
Eligibility
Sex/Gender
Male
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) 18 = Age = 65 years old, male; (2) Patients diagnosed clinically as CP/CPPS (see Appendix for diagnostic criteria); (3) Voluntarily sign an informed consent form before the start of activities related to this trial, understand the procedures and methods of this trial, and be willing to strictly follow the clinical trial protocol to complete this trial.
Exclusion criteria
Exclusion criteria: (1) Diseases that hinder safe participation in experimental design and affect the completion of research, such as myocardial infarction or stroke, severe heart failure, severe chronic obstructive pulmonary disease, cancer, severe systemic diseases, and severe mental illness in the past 3 months; (2) Patients who are known to be allergic to experimental drugs, cephalosporins, and sulfonamides; (3) Patients who develop asthma, urticaria, or allergic reactions after taking aspirin or other nonsteroidal anti-inflammatory drugs; (4) Patients with a history of gastrointestinal bleeding or perforation after using nonsteroidal anti-inflammatory drugs; (5) Patients with active gastrointestinal ulcers/bleeding, or those who have previously experienced recurrent ulcers/bleeding; (6) Perioperative patients undergoing coronary artery bypass surgery; (7) Individuals with a history of gastrointestinal obstruction, esophageal obstruction, or any degree of narrowing of the gastrointestinal lumen; (8) Currently participating in other clinical studies; (9) In addition to the above, the researchers have determined that patients who are not suitable to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NIH-CPSI; | — |
Secondary
| Measure | Time frame |
|---|---|
| IPSS;NRS;GAD-7 ;PHQ-9; | — |
Countries
China
Contacts
Public ContactDongjie Li
Xiangya Hospital,Central South Univerity
Outcome results
None listed